



US009066957B2

(12) **United States Patent**
Dalvi et al.

(10) **Patent No.:** **US 9,066,957 B2**
(45) **Date of Patent:** **Jun. 30, 2015**

(54) **DRY POWDER INHALER**

(71) Applicant: **Teva Branded Pharmaceutical Products R&D, Inc.**, Horsham, PA (US)

(72) Inventors: **Mukul Dalvi**, Miami, FL (US); **Seah Kee Tee**, Miami, FL (US)

(73) Assignee: **TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.**, Horsham, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/507,210**

(22) Filed: **Oct. 6, 2014**

(65) **Prior Publication Data**

US 2015/0099726 A1 Apr. 9, 2015

Related U.S. Application Data

(60) Provisional application No. 61/887,589, filed on Oct. 7, 2013, provisional application No. 61/888,301, filed on Oct. 8, 2013.

(51) **Int. Cl.**

A61K 31/57 (2006.01)
A61K 31/569 (2006.01)
A61K 31/137 (2006.01)
A61K 9/00 (2006.01)
A61M 15/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/569** (2013.01); **A61K 31/137** (2013.01); **A61K 9/0075** (2013.01); **A61M 15/0025** (2014.02); **A61M 15/0008** (2014.02); **A61M 15/0078** (2014.02); **A61M 15/0086** (2013.01); **A61M 2202/064** (2013.01); **A61K 31/57** (2013.01)

(58) **Field of Classification Search**

USPC 514/171; 128/203.15
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,395,300	B1 *	5/2002	Straub et al.	424/489
2004/0105821	A1 *	6/2004	Bernstein et al.	424/46
2005/0042171	A1 *	2/2005	Gavin et al.	424/46

FOREIGN PATENT DOCUMENTS

WO	0197889	12/2001
WO	0200281	1/2002
WO	2011054527	5/2011
WO	2011145109	11/2011

OTHER PUBLICATIONS

Invitation to pay additional fees and, where applicable, protest fee mailed Mar. 9, 2015 for International Application No. PCT/US2014/059285.

Nelson, H. S. et al., "Efficacy and safety of fluticasone propionate 44 1/4g/salmeterol 21 1/4g administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment," *Annals of Allergy, Asthma & Immunology*, vol. 91, No. 3, Sep. 1, 2003, pp. 263-269.

* cited by examiner

Primary Examiner — Raymond Henley, III

(74) *Attorney, Agent, or Firm* — RatnerPrestia

(57)

ABSTRACT

This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 µg; and wherein the dose provides a baseline-adjusted FEV₁ in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 µg; and wherein the dose provides a baseline-adjusted FEV₁ in a patient of more than 150 mL within 30 minutes of receiving the dose.

20 Claims, 12 Drawing Sheets